R

Revenio Group Oyj
OMXH:REG1V

Watchlist Manager
Revenio Group Oyj
OMXH:REG1V
Watchlist
Price: 22.75 EUR 0.89% Market Closed
Market Cap: 607m EUR

Revenio Group Oyj
Investor Relations

Revenio Group Oyj is a globally operating health technology, which engages in the detection of glaucoma, osteoporosis, skin cancer, and asthma. The company is headquartered in Vantaa, Etela-Suomen and currently employs 184 full-time employees. The company went IPO on 2003-01-01. The Company’s activities are divided into two business areas: Revenio Health Tech, which is responsible for the design, manufacture and sale of tonometers and bone density measurement devices; as well as Revenio Technology and Services, which provides contact center services for material handling systems. The company distributes products in a range of countries, including the United States, Canada, Australia, Japan and India. Furthermore, the Company is a parent of Done Medical Oy, Kauhajoen Sisalogistiikka Oy, Icare Finland Oy, Oscare Medical Oy and Midas Touch Oy, among others.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q1 2025
Call Date
Apr 29, 2025
AI Summary
Q1 2025

Strong Start: Revenio delivered a robust Q1 with net sales of EUR 26.1 million, up 10.5% year-on-year, and record profitability.

Broad-Based Growth: Sales grew in all regions, notably strong in China and India, with key products like tonometers and imaging devices performing well.

Margin Performance: EBIT reached EUR 6.6 million, representing 25.4% of revenue, and gross margin improved slightly due to accounting changes.

Tariff Impact Managed: Management estimates a EUR 0.8–1.4 million earnings impact from U.S. tariffs in Q2–Q4 if unmitigated, but plans price increases to offset this.

Product Launches: The new MAIA and TONOVET Pro devices are seeing positive early demand; microperimeter product was launched after FDA and CE approvals.

Guidance Maintained: Full-year guidance for 6–15% FX-adjusted net sales growth and good profitability remains unchanged.

Cost Increases: Higher personnel and marketing costs contributed to a 10% rise in fixed costs, partly due to headcount growth and salary hikes.

Key Financials
Net Sales
EUR 26.1 million
EBIT
EUR 6.6 million
EBIT Margin
25.4%
Interest-bearing Debt
EUR 11.3 million
Average Headcount
246
Earnings Call Recording
Other Earnings Calls

Management

Mr. Jouni Toijala B.Sc., M.B.A.
President & CEO
No Bio Available
Mr. Robin Pulkkinen M.Sc., M.Sc. (Econ)
Chief Financial Officer
No Bio Available
Mr. Ari Isomäki
Vice President of Operations
No Bio Available
Mr. Tomi Karvo M.B.A., M.Sc.
Vice President of Products, Brand & Marketing
No Bio Available
Mr. John Floyd
Vice President of Sales
No Bio Available
Ms. Hanna Vuornos
Vice President of People & Culture
No Bio Available
Kate Taylor
Vice President of Strategy & Business Development
No Bio Available

Contacts

Address
ETELA-SUOMEN
Vantaa
Ayritie 22
Contacts
+358987751150.0
www.reveniogroup.fi